

November 7, 1969

Dr. Robert A. Buchanan
Parke-Davis Research Laboratories
2800 Plymouth Road
Ann Arbor, Michigan 48106

Dear Dr. Buchanan:

Enclosed is a protocol approved by the appropriate committees of the College for the development of a psychopharmacology study in childhood and adolescent behavior disorders. Zarontin (ethosuximide) is one of the compounds that we are interested in testing in our initial studies.

Because of a desire to assure the delivery of medication to our patients, we are making every effort to provide the medications in liquid vehicle or concentrate form. In checking the PDR I note that Zarontin is not clinically available in concentrate form. In the event that such a concentrate is available for experimental purposes, we would request an opportunity to test it.

If not, we would consider its trial in capsule form and would request your support of this study in making available supplies of Zarontin and its placebo. Would it be possible to provide us with 12 bottles, 100 capsules each, of Zarontin and 6 bottles of placebo? If a liquid preparation is possible, I would like an opportunity to discuss its study.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp